tiprankstipranks
Verastem reports Q4 adjusted EPS ($1.10), consensus (62c)
PremiumThe FlyVerastem reports Q4 adjusted EPS ($1.10), consensus (62c)
1M ago
Verastem receives Orphan Drug Designation from FDA for avutometinib
PremiumThe Fly
Verastem receives Orphan Drug Designation from FDA for avutometinib
2M ago
Verastem treatment of low grade serous ovarian cancer granted orphan designation
PremiumThe Fly
Verastem treatment of low grade serous ovarian cancer granted orphan designation
2M ago
Verastem selects GFH375/VS-7375 as lead program of pact with GenFleet
PremiumThe FlyVerastem selects GFH375/VS-7375 as lead program of pact with GenFleet
4M ago
Verastem initiates RAMP 301 trial
PremiumThe Fly
Verastem initiates RAMP 301 trial
4M ago
Verastem assumed with a Buy at BTIG
PremiumThe Fly
Verastem assumed with a Buy at BTIG
5M ago
Verastem announces initial results of RAMP 203 trial of avutometinib, LUMAKRAS
PremiumThe FlyVerastem announces initial results of RAMP 203 trial of avutometinib, LUMAKRAS
6M ago
Verastem presents avutometinib and defactinib combination program updates
PremiumThe Fly
Verastem presents avutometinib and defactinib combination program updates
7M ago
Verastem initiated with a Buy at B. Riley
PremiumThe Fly
Verastem initiated with a Buy at B. Riley
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100